Targeting LDH enzymes with a stiripentol analog to treat epilepsy

Science

Volumn 347, Issue 6228, 2015, Pages 1362-1367

  Sada, Nagisa ^a   Lee, Suni ^b   Katsu, Takashi ^a,c   Otsuki, Takemi ^b   Inoue, Tsuyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ISOSAFROLE; LACTATE DEHYDROGENASE; OXAMIC ACID; PYRUVIC ACID; STIRIPENTOL; 1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT; ENZYME INHIBITOR; SAFROLE;

DRUG RESISTANCE; ENZYME ACTIVITY; INHIBITOR; METABOLISM; NEUROLOGY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BASAL GANGLION; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ELECTRIC POTENTIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; EPILEPSY; EPILEPTIC DISCHARGE; EXCITATORY POSTSYNAPTIC POTENTIAL; GAP JUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; HIPPOCAMPUS; HYPERPOLARIZATION; IN VITRO STUDY; IN VIVO STUDY; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; KETOGENIC DIET; LOCAL FIELD POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; PYRAMIDAL NERVE CELL; REGULATORY MECHANISM; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MEMBRANE POTENTIAL; NERVE CELL; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; SEIZURES;

ANIMALS; ANTICONVULSANTS; DIOXOLANES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; L-LACTATE DEHYDROGENASE; MEMBRANE POTENTIALS; MICE; MICE, INBRED ICR; NEURONS; PATCH-CLAMP TECHNIQUES; SAFROLE; SEIZURES; SUBTHALAMIC NUCLEUS;

EID: 84925334416     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaa1299     Document Type: Article

References (31)

1. P. Kwan, M. J. Brodie, N. Engl. J. Med. 342, 314-319 (2000).
2. E. G. Neal et al., Lancet Neurol. 7, 500-506 (2008).
3. W. Ma, J. Berg, G. Yellen, J. Neurosci. 27, 3618-3625 (2007).
4. G. R. Tanner, A. Lutas, J. R. Martínez-Franc¸ois, G. Yellen, J. Neurosci. 31, 8689-8696 (2011).
5. A. Giménez-Cassina et al., Neuron 74, 719-730 (2012).
6. N. Juge et al., Neuron 68, 99-112 (2010).
7. S. A. Masino et al., J. Clin. Invest. 121, 2679-2683 (2011).
8. A. Lutas, G. Yellen, Trends Neurosci. 36, 32-40 (2013).
9. B. S. Meldrum, M. A. Rogawski, Neurotherapeutics 4, 18-61 (2007).
10. K. J. Bough et al., Ann. Neurol. 60, 223-235 (2006).
11. Materials and methods are available as supplementary materials on Science Online.
12. D. Dybdal, K. Gale, J. Neurosci. 20, 6728-6733 (2000).
13. M. J. Iadarola, K. Gale, Science 218, 1237-1240 (1982).
14. I. A. Silver, M. Erecińska, J. Neurosci. 14, 5068-5076 (1994).
15. Z. Song, B. E. Levin, J. J. McArdle, N. Bakhos, V. H. Routh, Diabetes 50, 2673-2681 (2001).
16. M. O. Cunningham et al., Proc. Natl. Acad. Sci. U.S.A. 103, 5597-5601 (2006).
17. M. Bélanger, I. Allaman, P. J. Magistretti, Cell Metab. 14, 724-738 (2011).
18. N. Rouach, A. Koulakoff, V. Abudara, K. Willecke, C. Giaume, Science 322, 1551-1555 (2008).
19. M. P. Parsons, M. Hirasawa, J. Neurosci. 30, 8061-8070 (2010).
20. A. Suzuki et al., Cell 144, 810-823 (2011).
21. H. Shimizu et al., Neuron 54, 59-72 (2007).
22. T. K. Lam, R. Gutierrez-Juarez, A. Pocai, L. Rossetti, Science 309, 943-947 (2005).
23. R. D'Ambrosio, J. Wenzel, P. A. Schwartzkroin, G. M. McKhann 2nd, D. Janigro, J. Neurosci. 18, 4425-4438 (1998).
24. V. Riban et al., Neuroscience 112, 101-111 (2002).
25. R. Samala, J. Klein, K. Borges, Neurochem. Int. 58, 5-8 (2011).
26. C. Chiron et al., Lancet 356, 1638-1642 (2000).
27. R. H. Caraballo et al., Epilepsia 46, 1539-1544 (2005).
28. L. M. Deck et al., J. Med. Chem. 41, 3879-3887 (1998).
29. C. Granchi et al., J. Med. Chem. 54, 1599-1612 (2011).
30. M. K. Trojnar, K. Wojtal, M. P. Trojnar, S. J. Czuczwar, Pharmacol. Rep. 57, 154-160 (2005).
31. P. P. Quilichini, C. Chiron, Y. Ben-Ari, H. Gozlan, Epilepsia 47, 704-716 (2006).